Lung and Vascular Inflammation Section, Laboratory of Allergic Diseases (E.C.C., A.J.A., A.D., K.M.D.), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD.
Department of Emergency Medicine, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA (C.C.G., N.S., X.C., R.K.).
Arterioscler Thromb Vasc Biol. 2024 Dec;44(12):2628-2646. doi: 10.1161/ATVBAHA.124.321522. Epub 2024 Oct 31.
Vascular leakage is a deadly complication of severe infections, ranging from bacterial sepsis to malaria. Worldwide, septicemia is among the top 10 causes of lethality because of the shock and multiorgan dysfunction that arise from the host vascular response. In the monoclonal gammopathy-associated capillary leak syndrome (MG-CLS), even otherwise mundane infections induce recurrent septic-like episodes of profound microvascular hyperpermeability and shock. There are no defined genetic risk factors for MG-CLS or effective treatments for acute crises.
We characterized predicted loss-of-function mutations in PARP15 (poly[ADP-ribose] polymerase 15), a protein of unknown function that is absent in mice, in patients with MG-CLS. We analyzed barrier function in PARP15-deficient vascular endothelial cells and vascular leakage in mice engineered to express wild-type or loss-of-function variant human PARP15.
We discovered several loss-of-function PARP15 variants associated with MG-CLS. These mutations severely reduced PARP15 enzymatic function. The presence of the most frequently detected variant (G628R) correlated with clinical markers of severe vascular leakage. In human microvascular endothelial cells, PARP15 suppressed cytokine-induced barrier disruption by ADP-ribosylating the scaffold protein JIP3 (c-Jun N-terminal kinase-interacting protein 3) and inhibiting p38 MAP (mitogen-activated protein) kinase activation. Mice expressing enzymatically inactive human PARP15(G628R) were significantly more prone to inflammation-associated vascular leakage than mice expressing wild-type PARP15 in a p38-dependent fashion.
represents a previously unrecognized genetic susceptibility factor for MG-CLS. PARP15-mediated ADP ribosylation is an essential and genetically determined mechanism of the human vascular response to inflammation.
血管渗漏是严重感染的一种致命并发症,范围从细菌性败血症到疟疾。在全球范围内,败血症是导致死亡的十大原因之一,因为宿主血管反应引起的休克和多器官功能障碍。在单克隆丙种球蛋白相关性毛细血管渗漏综合征(MG-CLS)中,即使是平常的感染也会引起反复发作的类似败血症的严重微血管高通透性和休克。MG-CLS 或急性危象没有明确的遗传风险因素或有效治疗方法。
我们在 MG-CLS 患者中描述了 PARP15(多聚[ADP-核糖]聚合酶 15)的预测失功能突变,PARP15 是一种未知功能的蛋白,在小鼠中缺失。我们分析了 PARP15 缺陷型血管内皮细胞的屏障功能和表达野生型或失功能变异型人 PARP15 的小鼠的血管渗漏。
我们发现了几种与 MG-CLS 相关的 PARP15 失功能变体。这些突变严重降低了 PARP15 的酶活性。最常检测到的变体(G628R)的存在与严重血管渗漏的临床标志物相关。在人微血管内皮细胞中,PARP15 通过 ADP-核糖基化支架蛋白 JIP3(c-Jun N-末端激酶相互作用蛋白 3)和抑制 p38 MAP(丝裂原激活蛋白)激酶激活来抑制细胞因子诱导的屏障破坏。表达酶失活的人 PARP15(G628R)的小鼠比表达野生型 PARP15 的小鼠更容易发生炎症相关的血管渗漏,这是一种依赖于 p38 的方式。
PARP15 代表了 MG-CLS 的一个以前未被认识的遗传易感性因素。PARP15 介导的 ADP 核糖基化是人类血管对炎症反应的一个必要的和遗传决定的机制。